Sun Pharmaceutical Industries is expected to deliver double-digit revenue growth in the fourth quarter of fiscal year 2026. This growth is attributed to strong performances across its speciality drugs segment, domestic formulations, and emerging markets. Brokerages have highlighted the strength of Sun Pharma's US portfolio and the contribution of new product launches, including Unloxcyt. Despite higher research and development expenses, the company is projected to maintain a steady margin outlook. The diversified global business momentum is anticipated to support EBITDA growth, reflecting Sun Pharma's strategic focus on speciality therapies and expanding market presence. Sun Pharma is expected to post double-digit revenue growth in Q4FY26, driven by strong performance across speciality drugs, domestic formulations, and emerging markets.